Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Head and Neck Neoplasms
Description
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651) MeSH
Hierarchy View
Subtype Terms (8)
Esophageal Neoplasms
521 drugs (187 approved, 334 experimental)
Mouth Neoplasms
69 drugs (45 approved, 24 experimental)
Otorhinolaryngologic Neoplasms
3 drugs (2 approved, 1 experimental)
Parathyroid Neoplasms
12 drugs (10 approved, 2 experimental)
Squamous Cell Carcinoma of Head and Neck
519 drugs (158 approved, 361 experimental)
Thyroid Neoplasms
205 drugs (125 approved, 80 experimental)
Tracheal Neoplasms
3 drugs (2 approved, 1 experimental)
Approved Indicated Drugs (3)
Phase 4 Indicated Drugs (28)
Phase 3 Indicated Drugs (68)
Phase 2 Indicated Drugs (156)
acetylsalicylic acid (aspirin)
ad5f35-lmp1/lmp2-transduced autologous dendritic cells
autologous epstein-barr virus-specific cytotoxic t lymphocytes
Phase 1 Indicated Drugs (138)
allogeneic natural killer cells
autologous cd34+ cells transduced withpsrs11.efs.il2rg.pre
autologous genetically modified mage a10c796 t cells
autologous genetically modified mage a4c1032 t cells
cngrc peptide-tnf alpha conjugate
ebna1 c-terminal/lmp2 chimeric protein-expressing recombinant modified vaccinia ankara vaccine
genetically modified mesenchymal stem cell
Other Experimental Indicated Drugs (28)
Organization Involved with Phase 4 Indications (27)
Organization Involved with Phase 3 Indications (138)
Adlai Nortye Biopharma Co., Ltd.
Arbeitsgemeinschaft medikamentoese Tumortherapie
Blueprint Medicines Corporation
Case Western Reserve University
Ciusss de L'Est de l'Île de Montréal
Danish Head and Neck Cancer Group
Department of Radiation Oncology
Eastern Cooperative Oncology Group
Groupe Oncologie Radiotherapie Tete et Cou
Grup per l'Estudi dels Limfomes de Catalunya i Balears
Guangzhou Double Bioproducts Co., Ltd
Hoosier Cancer Research Network
Institut de Cancerologie de l'Ouest Paul Papin
Katholieke Universiteit Leuven
Ligue contre le cancer, France
L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A.
Newfoundland Cancer Treatment & Research Foundation
Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre
Radiation Therapy Oncology Group
Radiotherapeutisch Instituut Friesland
Radius Hungaricus Oncology Group
Royal Marsden Hospital NHS Trust
Swiss Group for Clinical Cancer Research
Taichung Veterans General Hospital
The Christie NHS Foundation Trust
Trans Tasman Radiation Oncology Group
Organization Involved with Phase 2 Indications (254)
Advanced Clinical Research Inc.
Assistance Publique - Hôpitaux de Paris
Azienda Ospedaliera S. Croce e Carle Cuneo
Badalona Hospital Germans Trias i Pujol
BioMimetix Pharmaceutical, Inc.
Brazilian Society of Clinical Oncology
Centre Georges Francois Leclerc
Centre Hospitalier de Saint-Brieuc
Chao Family Comprehensive Cancer Center
Chengdu Shi Endor Biological Engineering Technology Co., Ltd
China International Medical Foundation
Chinese Academy of Medical Sciences
Chinese Society of Clinical Oncology
City of Hope National Medical Center
Clinica Universidad de Navarra
Clinique de l' Estuaire, Pornichet
Coastal Carolina Radiation Oncology
Cyprus University of Technology
Dynavax Technologies Corporation
Fundação de Amparo à Pesquisa do Estado de São Paulo
General Drug House Ltd., Bangkok
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Gruppo Oncologico del Nord-Ovest
Holy Name Medical Center, Teaneck, NJ
Huazhong University of Science and Technology
Icahn School of Medicine at Mount Sinai
Instituto do Cancer do Estado de São Paulo
Istituto Nazionale per lo Studio e la Cura dei Tumori
James Graham Brown Cancer Center
Jiangsu Cancer Institute & Hospital
Mashhad University of Medical Sciences
Medical University of South Carolina
National Cheng Kung University
National Comprehensive Cancer Network
National Institute of Dental and Craniofacial Research (NIDCR)
National Institutes of Health (NIH)
New Hanover Regional Medical Center
Ontario Institute for Cancer Research
Papworth Hospital NHS Foundation Trust
Polyclinique du Parc, 31078 Toulouse, France
Professional Compounding Centers of America
Shanghai Xuhui District Central Hospital
Shenzhen SiBiono GeneTech Co.,Ltd
Shin Kong Wu Ho-Su Memorial Hospital
State University of New York, Buffalo
State University of New York, Syracuse
Taipei Veteran General hospital
The University of Texas, Dallas
Universidad Autonoma de Madrid
Universidad Complutense de Madrid
Université catholique de Louvain
University of California, San Diego
University of California, San Francisco
University of Colorado, Denver
University of Illinois at Chicago
University of Medicine and Dentistry of New Jersey
University of Nice Sophia Antipolis
University of North Carolina at Chapel Hill
University of Picardie Jules Verne
University of Southern Denmark
University of Texas, San Antonio
Val d'Aurelle Cancer Institute
Organization Involved with Phase 1 Indications (74)
American Society of Clinical Oncology
Australian National University
Baromedical Research Foundation
Cancer and Leukemia Group B (CALGB)
Cancer Immunotherapy Trials Network
Ichor Medical Systems Incorporated
Infinity Pharmaceuticals, Inc.
Instituto Nacional de Cancer, Brazil
Memorial Sloan-Kettering Cancer Center
National Institute for Health Research, United Kingdom
National Institute on Deafness and Other Communication Disorders (NIDCD)
Organization Involved with Other Experimental Indications (19)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
